Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study.
Soeria-Atmadja S et al.
British Journal of Clinical Pharmacology, 2025
Pharmacogenetics in Tuberculosis-HIV Coinfected Populations: A Systematic Review of Genetic Variants Influencing Antiretroviral and Anti-Tuberculosis Drug Response.
Hardi H et al.
Journal of Multidisciplinary Healthcare, 2025
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz.
Mardi P et al.
Genetics Research, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
The GenomeAsia 100K Project enables genetic discoveries across Asia.
Unknown Author
Nature, 2019
The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Helsby NA et al.
British Journal of Clinical Pharmacology, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Ahmad T et al.
Biochemical Pharmacology, 2018
Longrange PCR-based next-generation sequencing in pharmacokinetics and pharmacodynamics study of propofol among patients under general anaesthesia.
Zakerska-Banaszak O et al.
Scientific Reports, 2017
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.
Cho DY et al.
Drug Metabolism and Pharmacokinetics, 2016
PharmGKB summary: Efavirenz pathway, pharmacokinetics.
McDonagh EM et al.
Pharmacogenetics and Genomics, 2015
Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.
Čolić A et al.
Drug Metabolism Reviews, 2015
An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients.
Swart M et al.
Frontiers in Genetics, 2015
Pharmacogenetics of antiretroviral therapy.
Barreiro P et al.
Expert Opinion on Drug Metabolism & Toxicology, 2014
Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
Mukonzo JK et al.
Plos One, 2014
Evaluation of influence of single nucleotide polymorphisms in cytochrome P450 2B6 on substrate recognition using computational docking and molecular dynamics simulation.
Kobayashi K et al.
Plos One, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
Swart M et al.
Pharmacogenetics and Genomics, 2013
CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Levran O et al.
Addiction Biology, 2013
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
Mukonzo JK et al.
Bmc Infectious Diseases, 2013
Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools.
Radloff R et al.
Human Mutation, 2013
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M et al.
Pharmacogenetics and Genomics, 2013
HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.
Mukonzo JK et al.
Clinical Pharmacokinetics, 2011
The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy.
Cabrera Figueroa S et al.
Therapeutic Drug Monitoring, 2010
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
Ribaudo HJ et al.
The Journal of Infectious Diseases, 2010
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.
Mukonzo JK et al.
British Journal of Clinical Pharmacology, 2009
Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.
Talakad JC et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.
Wang H et al.
Current Drug Metabolism, 2008
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M et al.
Pharmacogenetics and Genomics, 2007
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
Rotger M et al.
Clinical Pharmacology and Therapeutics, 2007
MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms.
Blievernicht JK et al.
Clinical Chemistry, 2007
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.
Klein K et al.
Pharmacogenetics and Genomics, 2005
Impact of genetic polymorphism in relation to other factors on expression and function of human drug-metabolizing p450s.
Zanger UM et al.
Toxicology Mechanisms and Methods, 2005
Haplotype structure and allele frequencies of CYP2B6 in a Korean population.
Cho JY et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2004
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles.
Lang T et al.
The Journal of Pharmacology and Experimental Therapeutics, 2004
Overview of the pharmacogenetics of HIV therapy.
Rodríguez-Nóvoa S et al.
The Pharmacogenomics Journal, 0